Clinical Trial Detail

NCT ID NCT03091192
Title Savolitinib vs. Sunitinib in MET-driven PRCC.
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

papillary renal cell carcinoma

Therapies

Sunitinib

Savolitinib

Age Groups: senior adult

Additional content available in CKB BOOST